The protective effect of telmisartan in Type 2 diabetes rat kidneys is related to the downregulation of thioredoxin-interacting protein

Journal of Endocrinological Investigation

Volumn 36, Issue 7, 2013, Pages 453-459

  Wu, J ^a   Lin, H ^a   Liu, D ^a   Liu, J ^a   Wang, N ^a   Mei, X ^a   Sun, J ^a   Yang, G ^a   Zhang, X ^a  

^a THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Oxidative stress; Telmisartan; Thioredoxin; Thioredoxin interacting protein

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TELMISARTAN; THIOREDOXIN; THIOREDOXIN INTERACTING PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; ENZYME ACTIVITY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT; RECEPTOR DOWN REGULATION; RENAL PROTECTION; SYSTEMATIC REVIEW; UPREGULATION; WESTERN BLOTTING;

ANIMALS; BENZIMIDAZOLES; BENZOATES; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOWN-REGULATION; MALE; MALONDIALDEHYDE; NADPH OXIDASE; OXIDATIVE STRESS; PPAR GAMMA; RATS; RATS, SPRAGUE-DAWLEY; THIOREDOXINS;

EID: 84881458535     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/8764     Document Type: Article

References (33)

1. Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57: 1446-51.
2. Advani A, Gilbert RE, Thai K, et al. Expression, localization, and function of the thioredoxin system in diabetic nephropathy. J Am Soc Nephrol 2009, 20: 730-41.
3. Hamada Y, Miyata S, Nii-Kono T, et al. Overexpression of thioredoxin1 in transgenic mice suppresses development of diabetic nephropathy. Nephrol Dial Transplant 2007, 22: 1547-57.
4. Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 2004, 279: 30369-74.
5. Patwari P, Higgins LJ, Chutkow WA, Yoshioka J, Lee RT. The interaction of thioredoxin with Txnip. Evidence for formation of a mixed disulfide by disulfide exchange. J Biol Chem 2006, 281: 21884-91.
6. Fang S, Jin Y, Zheng H, et al. High glucose condition upregulated Txnip expression level in rat mesangial cells through ROS/MEK/MAPK pathway. Mol Cell Biochem 2011, 347: 175-82.
7. Qi W, Chen X, Gilbert RE, et al. High glucose-induced thioredoxin-interacting protein in renal proximal tubule cells is independent of transforming growth factor-beta1. Am J Pathol 2007, 171: 744-54.
8. Lakshmanan AP, Watanabe K, Thandavarayan RA, et al. Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) Mas receptor expression associated with its PPAR-gamma agonist action. Free Radic Res 2011, 45: 575-84.
9. Nishiyama A, Nakagawa T, Kobori H, et al. Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. J Hypertens 2008, 26: 1849-59.
10. Hasegawa G, Fukui M, Hosoda H, et al. Telmisartan, an angiotensin II type 1 receptor blocker, prevents the development of diabetes in male Spontaneously Diabetic Torii rats. Eur J Pharmacol 2009, 605: 164-9.
11. Nakayama M, Inoguchi T, Sonta T, et al. Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochem Biophys Res Commun 2005, 332: 927-33.
12. Wenzel P, Schulz E, Oelze M, et al. AT1-receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med 2008, 45: 619-26.
13. Benson SC, Pershadsingh HA, Ho CI, et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004, 43: 993-1002.
14. Matsui T, Yamagishi S, Ueda S, et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 2007, 35: 482-9.
15. Watanabe M, Inukai K, Sumita T, et al. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients. Intern Med 2010, 49: 1843-7.
16. Qi W, Chen X, Holian J, Tan CY, Kelly DJ, Pollock CA. Transcription factors Kruppel-like factor 6 and peroxisome proliferator-activated receptor-{gamma} mediate high glucose-induced thioredoxin-interacting protein. Am J Pathol 2009, 175: 1858-67.
17. Billiet L, Furman C, Larigauderie G, et al. Enhanced VDUP-1 gene expression by PPARgamma agonist induces apoptosis in human macrophage. J Cell Physiol 2008, 214: 183-91.
18. Oka S, Masutani H, Liu W, et al. Thioredoxin-binding protein-2-like inducible membrane protein is a novel vitamin D3 and peroxisome proliferator-activated receptor (PPAR)gamma ligand target protein that regulates PPARgamma signaling. Endocrinology 2006, 147: 733-43.
19. Chutkow WA, Birkenfeld AL, Brown JD, et al. Deletion of the alphaarrestin protein Txnip in mice promotes adiposity and adipogenesis while preserving insulin sensitivity. Diabetes 2010, 59: 1424-34.
20. Yang XY, Sun L, Xu P, et al. Effects of salvianolic acid A on plantar microcirculation and peripheral nerve function in diabetic rats. Eur J Pharmacol 2011, 665: 40-6.
21. Chu KY, Lau T, Carlsson PO, Leung PS. Angiotensin II type 1 receptor blockade improves beta-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 2006, 55: 367-74.
22. Li JM, Shah AM. Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells. J Biol Chem 2002, 277: 19952-60.
23. Zhang L, Tu H, Li YL. Angiotensin II enhances hyperpolarizationactivated currents in rat aortic baroreceptor neurons: involvement of superoxide. Am J Physiol Cell Physiol 2009, 298: C98-106.
24. Yamawaki H, Berk BC. Thioredoxin: a multifunctional antioxidant enzyme in kidney, heart and vessels. Curr Opin Nephrol Hypertens 2005, 14: 149-53.
25. Panchapakesan U, Sumual S, Pollock CA, et al. PPARγ agonists exert antifibrotic effects in renal tubular cells exposed to high glucose. Am J Physiol Renal Physiol 2005, 289: F1153-8.
26. Cha DR, Zhang X, Zhang Y, et al. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. Diabetes 2007, 56: 2036-45.
27. Gokulakrishnan K, Mohanavalli KT, Monickaraj F, Mohan V, Balasubramanyam M. Subclinical inflammation/oxidation as revealed by altered gene expression profiles in subjects with impaired glucose tolerance and Type 2 diabetes patients. Mol Cell Biochem 2009, 324: 173-81.
28. Kuppan G, Balasubramanyam J, Monickaraj F, Srinivasan G, Mohan V, Balasubramanyam M. Transcriptional regulation of cytokines and oxidative stress by gallic acid in human THP-1 monocytes. Cytokine 2010, 49: 229-34.
29. Saitoh Y, Hongwei W, Ueno H, Mizuta M, Nakazato M. Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Diabetes Metab 2009, 35: 392-7.
30. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000, 267: 6102-9.
31. Shaked M, Ketzinel-Gilad M, Ariav Y, Cerasi E, Kaiser N, Leibowitz G. Insulin counteracts glucotoxic effects by suppressing thioredoxin-interacting protein production in INS-1E beta cells and in Psammomys obesus pancreatic islets. Diabetologia 2009, 52: 636-44.
32. Saitoh Y, Hongwei W, Ueno H, et al. Telmisartan attenuates fatty-acid-induced oxidative stress and NAD(P)H oxidase activity in pancreatic beta-cells. Diabetes Metab 2009, 35: 392-7.
33. Storka A, Vojtassakova E, Mueller M, et al. Angiotensin inhibition stimulates PPARgamma and the release of visfatin. Eur J Clin Invest 2008, 38: 820-6.